Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prosp., Multic., Randomized, Open-label Trial to Assess the Safety, Tolerability and Efficacy of Dual Therapy With Boosted Darunavir + Dolutegravir When Switching From SOC ART in HIV-patients With Sustained Virological Suppr.

NCT02486133 is registered in ClinicalTrials.gov with Technical University of Munich as lead sponsor.

NCT NCT02486133
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02486133 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prosp., Multic., Randomized, Open-label Trial to Assess the Safety, Tolerability and Efficacy of Dual Therapy With Boosted Darunavir + Dolutegravir When Switching From SOC ART in HIV-patients With Sustained Virological Suppr.
Lead sponsor
Technical University of Munich
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2015
Completion date
May 31, 2018
Enrollment
269 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-infection